MA51520A - Dérivés de 1,3,4,5-tétrahydro-2h-pyrido[4,3-b]indole pour le traitement, le soulagement ou la prévention de troubles associés à des agrégats de tau comme la maladie d'alzheimer - Google Patents
Dérivés de 1,3,4,5-tétrahydro-2h-pyrido[4,3-b]indole pour le traitement, le soulagement ou la prévention de troubles associés à des agrégats de tau comme la maladie d'alzheimerInfo
- Publication number
- MA51520A MA51520A MA051520A MA51520A MA51520A MA 51520 A MA51520 A MA 51520A MA 051520 A MA051520 A MA 051520A MA 51520 A MA51520 A MA 51520A MA 51520 A MA51520 A MA 51520A
- Authority
- MA
- Morocco
- Prior art keywords
- pyrido
- tetrahydro
- alzheimer
- relief
- disease
- Prior art date
Links
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 title 2
- 208000024827 Alzheimer disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 title 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Testing Relating To Insulation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18150422 | 2018-01-05 | ||
| EP18175852 | 2018-06-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51520A true MA51520A (fr) | 2021-04-14 |
Family
ID=65010781
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051520A MA51520A (fr) | 2018-01-05 | 2019-01-04 | Dérivés de 1,3,4,5-tétrahydro-2h-pyrido[4,3-b]indole pour le traitement, le soulagement ou la prévention de troubles associés à des agrégats de tau comme la maladie d'alzheimer |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP3735411B1 (fr) |
| JP (2) | JP7225251B2 (fr) |
| KR (1) | KR102477105B1 (fr) |
| CN (1) | CN111757882B (fr) |
| AU (2) | AU2019205087B2 (fr) |
| BR (1) | BR112020012833A2 (fr) |
| CA (1) | CA3086759C (fr) |
| CL (1) | CL2020001796A1 (fr) |
| CO (1) | CO2020008287A2 (fr) |
| CR (1) | CR20200326A (fr) |
| EC (1) | ECSP20042640A (fr) |
| ES (1) | ES2989145T3 (fr) |
| IL (1) | IL275781B2 (fr) |
| JO (1) | JOP20200167A1 (fr) |
| MA (1) | MA51520A (fr) |
| MX (1) | MX2020007031A (fr) |
| NZ (1) | NZ765495A (fr) |
| PE (1) | PE20211090A1 (fr) |
| PH (1) | PH12020500573A1 (fr) |
| SG (1) | SG11202005607WA (fr) |
| WO (1) | WO2019134978A1 (fr) |
| ZA (1) | ZA202003769B (fr) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113453688A (zh) * | 2019-03-01 | 2021-09-28 | Ac免疫有限公司 | 用于治疗、减轻或预防与Tau聚集体相关的病症的新化合物 |
| CN110845457B (zh) * | 2019-10-22 | 2022-06-10 | 中国药科大学 | 松萝酸衍生物及其制法和在阿尔茨海默病药物中的应用 |
| CN112791078B (zh) * | 2019-11-13 | 2022-12-06 | 润佳（苏州）医药科技有限公司 | 同位素富集的3-氨基-1-丙磺酸及其衍生物的用途 |
| CA3172102A1 (fr) | 2020-03-19 | 2021-09-23 | Sonia Maria Poli | Traitements par dose des tauopathies |
| KR20230051168A (ko) * | 2020-07-02 | 2023-04-17 | 레믹스 테라퓨틱스 인크. | 2-(인다졸-5-일)-6-(피페리딘-4-일)-1,7-나프티리딘 유도체, 및 핵산 스플라이싱의 조절제로서의 및 증식성 질환의 치료를 위한 관련 화합물 |
| CN117015536A (zh) * | 2020-07-02 | 2023-11-07 | 雷密克斯医疗公司 | 作为核酸剪接和增殖性疾病治疗的调节剂的2-(吲唑-5-基)-6-(哌啶-4-基)-1,7-萘啶衍生物及相关化合物 |
| AR123730A1 (es) * | 2020-10-15 | 2023-01-04 | Ac Immune Sa | Compuestos novedosos |
| KR102231446B1 (ko) * | 2021-01-21 | 2021-03-24 | (주) 와이디생명과학 | 베타아밀로이드 및 타우 단백질 집적과 연관된 질환 치료용 약학적 조성물 |
| WO2023025109A1 (fr) * | 2021-08-23 | 2023-03-02 | 上海维申医药有限公司 | Inhibiteur du récepteur de type toll et sa préparation et son application |
| US20250092065A1 (en) * | 2022-01-05 | 2025-03-20 | Remix Therapeutics Inc. | 2-(indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as modulators for splicing nucleic acids and for the treatment of proliferative diseases |
| KR102856378B1 (ko) * | 2022-09-30 | 2025-09-08 | 주식회사 젬백스앤카엘 | 4r 타우병증의 치료 또는 예방용 펩티드 |
| EP4644396A1 (fr) * | 2022-12-28 | 2025-11-05 | Visionpharma (Nantong) Co., Ltd | Inhibiteur de récepteur de type toll, sa préparation et son application |
| WO2025134068A1 (fr) * | 2023-12-22 | 2025-06-26 | Ac Immune Sa | Conjugués anticorps-médicament ciblant des protéinopathies, et leurs utilisations |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ541282A (en) | 2002-12-24 | 2009-02-28 | Bellus Health International Ltd | Therapeutic formulations for the treatment of beta-amyloid related diseases |
| AR049300A1 (es) * | 2004-06-15 | 2006-07-12 | Schering Corp | Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos |
| JP2009527542A (ja) | 2006-02-23 | 2009-07-30 | ファイザー・プロダクツ・インク | Ｐｄｅ１０阻害薬としての置換キナゾリン |
| MX2010008198A (es) * | 2008-02-25 | 2010-08-23 | Hoffmann La Roche | Inhibidores de cinasa de pirrolopirazina. |
| US8853391B2 (en) | 2008-12-18 | 2014-10-07 | Merck Patent Gmbh | Tricyclic azaindoles |
| WO2011084439A1 (fr) * | 2009-12-17 | 2011-07-14 | Sanofi | Dérivés de tétrahydrocarboline comme inhibiteurs de l'eg5 |
| CA2794808C (fr) | 2010-04-16 | 2019-08-20 | Ac Immune S.A. | Composes destines au traitement de maladies associees aux proteines amyloides ou de type amyloide |
| WO2016090296A1 (fr) * | 2014-12-05 | 2016-06-09 | Subramaniam Ananthan | Composés hétérocycliques en tant que modulateurs du transport d'amines biogènes |
| EP3118202A1 (fr) * | 2015-07-15 | 2017-01-18 | AC Immune S.A. | Dérivés de dihydropyridopyrrole en tant que ligands tau-pet |
| WO2017009454A1 (fr) * | 2015-07-15 | 2017-01-19 | Ac Immune S.A. | Nouveaux composés d'imagerie |
-
2019
- 2019-01-04 EP EP19700206.6A patent/EP3735411B1/fr active Active
- 2019-01-04 AU AU2019205087A patent/AU2019205087B2/en active Active
- 2019-01-04 NZ NZ765495A patent/NZ765495A/en unknown
- 2019-01-04 JO JOP/2020/0167A patent/JOP20200167A1/ar unknown
- 2019-01-04 BR BR112020012833-3A patent/BR112020012833A2/pt not_active IP Right Cessation
- 2019-01-04 WO PCT/EP2019/050180 patent/WO2019134978A1/fr not_active Ceased
- 2019-01-04 MX MX2020007031A patent/MX2020007031A/es unknown
- 2019-01-04 CN CN201980007273.XA patent/CN111757882B/zh active Active
- 2019-01-04 MA MA051520A patent/MA51520A/fr unknown
- 2019-01-04 IL IL275781A patent/IL275781B2/en unknown
- 2019-01-04 SG SG11202005607WA patent/SG11202005607WA/en unknown
- 2019-01-04 PE PE2020000906A patent/PE20211090A1/es unknown
- 2019-01-04 ES ES19700206T patent/ES2989145T3/es active Active
- 2019-01-04 CR CR20200326A patent/CR20200326A/es unknown
- 2019-01-04 JP JP2020537162A patent/JP7225251B2/ja active Active
- 2019-01-04 KR KR1020207018988A patent/KR102477105B1/ko active Active
- 2019-01-04 CA CA3086759A patent/CA3086759C/fr active Active
-
2020
- 2020-06-22 ZA ZA2020/03769A patent/ZA202003769B/en unknown
- 2020-06-29 PH PH12020500573A patent/PH12020500573A1/en unknown
- 2020-07-03 CO CONC2020/0008287A patent/CO2020008287A2/es unknown
- 2020-07-03 CL CL2020001796A patent/CL2020001796A1/es unknown
- 2020-07-22 EC ECSENADI202042640A patent/ECSP20042640A/es unknown
-
2021
- 2021-05-24 AU AU2021203340A patent/AU2021203340B2/en active Active
-
2022
- 2022-08-10 JP JP2022127608A patent/JP2022172130A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| NZ765495A (en) | 2024-02-23 |
| ZA202003769B (en) | 2025-04-30 |
| JP2022172130A (ja) | 2022-11-15 |
| WO2019134978A1 (fr) | 2019-07-11 |
| EP3735411A1 (fr) | 2020-11-11 |
| PH12020500573A1 (en) | 2021-05-10 |
| AU2019205087B2 (en) | 2021-06-10 |
| CA3086759C (fr) | 2025-06-17 |
| JP2021510151A (ja) | 2021-04-15 |
| IL275781B1 (en) | 2023-11-01 |
| KR20200096570A (ko) | 2020-08-12 |
| AU2019205087A1 (en) | 2020-07-02 |
| AU2021203340B2 (en) | 2022-11-24 |
| CR20200326A (es) | 2020-12-09 |
| EP3735411B1 (fr) | 2024-07-10 |
| JP7225251B2 (ja) | 2023-02-20 |
| AU2021203340A1 (en) | 2021-06-24 |
| ECSP20042640A (es) | 2020-09-30 |
| CN111757882B (zh) | 2023-08-22 |
| PE20211090A1 (es) | 2021-06-14 |
| BR112020012833A2 (pt) | 2021-01-05 |
| IL275781B2 (en) | 2024-03-01 |
| SG11202005607WA (en) | 2020-07-29 |
| CO2020008287A2 (es) | 2020-10-30 |
| MX2020007031A (es) | 2020-12-03 |
| JOP20200167A1 (ar) | 2022-10-30 |
| ES2989145T3 (es) | 2024-11-25 |
| IL275781A (en) | 2020-08-31 |
| KR102477105B1 (ko) | 2022-12-13 |
| CA3086759A1 (fr) | 2019-07-11 |
| CL2020001796A1 (es) | 2021-01-22 |
| CN111757882A (zh) | 2020-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51520A (fr) | Dérivés de 1,3,4,5-tétrahydro-2h-pyrido[4,3-b]indole pour le traitement, le soulagement ou la prévention de troubles associés à des agrégats de tau comme la maladie d'alzheimer | |
| EP3837359A4 (fr) | Méthodes et compositions pour le traitement d'une maladie mitochondriale ou de troubles mitochondriaux et hétéroplasmie | |
| EP3870170A4 (fr) | Méthodes et compositions pour le traitement de la presbytie, de la mydriase et d'autres troubles oculaires | |
| MA50786A (fr) | Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques | |
| MA53937A (fr) | Compositions comprenant des souches bactériennes | |
| MA49279A (fr) | Compositions d'anticorps optimisées pour le traitement de troubles oculaires | |
| EP3504204A4 (fr) | Indazolyl-l,2,4-thiadiazolamines et composés apparentés pour l'inhibition de protéine kinase associée à rho et le traitement de la maladie | |
| EA201990450A1 (ru) | Ингибиторы киназы, содержащей домен с двумя лейциновыми "застежками-молниями" (dlk), для лечения заболевания | |
| EP4301747A4 (fr) | Dérivés d'indole en tant qu'agents sérotoninergiques utiles pour le traitement de troubles associés à ceux-ci | |
| MA53739A (fr) | Composition et son utilisation pour le traitement de la maladie de parkinson et de troubles apparentés | |
| EP4081201A4 (fr) | Composition pharmaceutique pour le traitement ou la prévention de nombreux troubles inflammatoires | |
| MA52482B1 (fr) | Dérivés de spiropipéridine en tant que modulateurs allostériques des récepteurs nicotiniques de l'acétylcholine | |
| EP3695847A4 (fr) | Composition comprenant de l'huile essentielle de fleur de vergerette annuelle pour la prévention et le traitement d'une maladie neuromusculaire | |
| MA54447A (fr) | Dérivés de 7-phénoxy-n-(3-azabicyclo[3.2.1]octan-8-yl)-6,7-dihydro-5h-pyrrolo[1,2-b][1,2,4]triazol-2-amine et composés apparentés en tant que modulateurs de gamma-sécrétase pour le traitement de la maladie d'alzheimer | |
| EP4052694A4 (fr) | Composition de gouttes oculaires pour la prévention ou le traitement d'une maladie oculaire | |
| MA55351A (fr) | Nouveaux composés pour le traitement, le soulagement ou la prévention de troubles associés à des agrégats de protéine tau | |
| WO2022093552A3 (fr) | Agonistes rev-erb | |
| EP3785718A4 (fr) | Composition pharmaceutique pour la prévention ou le traitement d'une maladie infectieuse de flavivirus | |
| EP3838272A4 (fr) | Composition pour la prévention ou le traitement d'une maladie neurodégénérative | |
| EP3996729C0 (fr) | Composition pour la prévention ou le traitement de la dépression ou de l'anxiété | |
| WO2017103892A3 (fr) | Composition pour traiter et prévenir des maladies neurologiques, la neuroinflammation et la maladie d'alzheimer | |
| MA39524A1 (fr) | 1h-1,8-naphthyridin-2 ones utilisées comme composés anti prolifératifs | |
| MA30662B1 (fr) | Derives de phenyl-prenyl-ether pour le traitement de maladies ou troubles cognitifs, neurodegeneratifs ou neuronaux | |
| EP3858359A4 (fr) | Composition, comprenant un dérivé de thiamine, pour la prévention ou le traitement de l'hypercortisolémie | |
| EP3752614A4 (fr) | Thérapie oligonucléotidique pour la maladie de wilson |